Understanding treatment strategies and preferences in nonmetastatic castration-resistant prostate cancer from the Japanese physician perspective
K Suzuki, V Grillo, Y Chen, S Singh… - JCO global …, 2021 - ascopubs.org
PURPOSE Sixteen percent (16%) of patients with castration-resistant prostate cancer
(CRPC) show no bone metastasis at diagnosis. However, 33% will become metastatic within …
(CRPC) show no bone metastasis at diagnosis. However, 33% will become metastatic within …
Understanding Treatment Strategies and Preferences in Nonmetastatic Castration-Resistant Prostate Cancer From the Japanese Physician Perspective
K Suzuki, V Grillo, Y Chen, S Singh… - JCO Global Oncology, 2021 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> PURPOSE</jats: title>< jats: p> Sixteen percent (16%) of
patients with castration-resistant prostate cancer (CRPC) show no bone metastasis at …
patients with castration-resistant prostate cancer (CRPC) show no bone metastasis at …
Understanding Treatment Strategies and Preferences in Nonmetastatic Castration-Resistant Prostate Cancer From the Japanese Physician Perspective.
K Suzuki, V Grillo, Y Chen, S Singh… - JCO Global …, 2021 - europepmc.org
Purpose Sixteen percent (16%) of patients with castration-resistant prostate cancer (CRPC)
show no bone metastasis at diagnosis. However, 33% will become metastatic within 2 years …
show no bone metastasis at diagnosis. However, 33% will become metastatic within 2 years …
Understanding Treatment Strategies and Preferences in Nonmetastatic Castration-Resistant Prostate Cancer From the Japanese Physician Perspective
K Suzuki, V Grillo, Y Chen, S Singh… - JCO global …, 2021 - pubmed.ncbi.nlm.nih.gov
Purpose Sixteen percent (16%) of patients with castration-resistant prostate cancer (CRPC)
show no bone metastasis at diagnosis. However, 33% will become metastatic within 2 years …
show no bone metastasis at diagnosis. However, 33% will become metastatic within 2 years …
[HTML][HTML] Understanding Treatment Strategies and Preferences in Nonmetastatic Castration-Resistant Prostate Cancer From the Japanese Physician Perspective
K Suzuki, V Grillo, Y Chen, S Singh… - JCO Global …, 2021 - ncbi.nlm.nih.gov
PURPOSE Sixteen percent (16%) of patients with castration-resistant prostate cancer
(CRPC) show no bone metastasis at diagnosis. However, 33% will become metastatic within …
(CRPC) show no bone metastasis at diagnosis. However, 33% will become metastatic within …